1 / 3

Supplementary Figure 1

Supplementary Figure 1. D. B. A. C. 3 (51 ～ 75%). 2 (26 ～ 50%). 1 (1 ～ 25%). 4 (76 ～ 100%). E. F. G. H. 3 (strong). 2 (moderate). 0 (negative). 1 (weak). Supplementary Figure 2. A. SW480. HT29. C. D. ANGPTL2/GAPDH. ANGPTL2/GAPDH. ANGPTL2/GAPDH. E. B. F. SW480. HT29.

tanner-delacruz
Download Presentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure 1 D B A C 3 (51～75%) 2 (26～50%) 1 (1～25%) 4 (76～100%) E F G H 3 (strong) 2 (moderate) 0 (negative) 1 (weak)

  2. Supplementary Figure 2 A SW480 HT29 C D ANGPTL2/GAPDH ANGPTL2/GAPDH ANGPTL2/GAPDH E B F SW480 HT29 ANGPTL2 (OD) ANGPTL2 (OD) ANGPTL2 (OD)

  3. Supplementary Figure 3 A B Stage I CRC patients with CEA <5 CRC patients with CEA <5 100 100 80 80 60 60 Sensitivity Sensitivity 40 40 20 20 AUC = 0.804 AUC = 0.859 0 0 0 20 40 60 80 100 0 20 40 60 80 100 100-Specificity 100-Specificity

More Related